EVElizabeth M. Vaughan

Elizabeth M. Vaughan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth M. Vaughan has a total of 160 co-authors. Here are the top co-authors by number of shared publications:

  • Aanand D. Naik

    Department of Management, Policy, and Community Health, UT Health Houston School of Public Health, Houston, Texas

    7 shared publications
  • Craig A. Johnston

    Department of Health and Human Performance, University of Houston, Houston, Texas

    7 shared publications
  • John P. Foreyt

    Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine (Baylor), Houston, USA

    7 shared publications
  • Laura Porterfield

    Department of Family Medicine, University of Texas Medical Branch , Galveston, Texas

    7 shared publications
  • Xiaoying Yu

    Department of Biostatistics & Data Science, University of Texas Medical Branch, Galveston

    6 shared publications
  • Laura Porterfield

    Department of Family Medicine and Community Health, University of Texas Medical Branch, Galveston, USA

    5 shared publications

Latest Publications

  • Open Access

    Cost-Effectiveness of Community Health Worker Interventions for Type 2 Diabetes Mellitus: A Systematic Review

    by Laura R. Porterfield, H. Shelton Brown, Dallin Swanson, Revathi Gnanasekaran, Patricia Rodriguez Espinosa, Xiaoying Yu, Elizabeth M. Vaughan

  • Compare diabetes care patterns by primary care accessibility during the COVID ‐19 pandemic

    by Wei‐Chen Lee, Laura R. Porterfield, Elizabeth M. Vaughan, Mukaila Raji

    Purpose: The COVID‐19 pandemic disrupted primary care delivery and may have exacerbated disparities in chronic disease management, particularly for diabetes mellitus. This study sought to investigate how living in areas with low access to primary care providers (PCP) affected the delivery of diabetes care during the pandemic. Methods: This is a retrospective longitudinal study using the Panel 24 of the Medical Expenditure Panel Survey data merged with the 2019 County Health Rankings data to classify areas by PCP availability (low vs. high). Dependent variables included measures of care processes (e.g., number of HbA1c tests), quality (e.g., diet modification) and outcomes (e.g., eye complications). Multivariable models were adjusted for demographics, insurance status and COVID‐19 diagnosis. Findings: HbA1c testing, foot examinations and retinal examinations decreased during the pandemic for both groups, with much more pronounced declines in low PCP density areas. The largest change occurred in the frequency of attending group classes, dropping nearly 80% in low PCP areas. Individuals in low PCP areas were more likely to initiate oral diabetes medications (as opposed to insulin) compared with those in high PCP areas (0.84% vs. 0.28%, p = 0.015). Older age was associated with new diabetes (HR = 1.05) and new kidney disease (HR = 1.04), but less likely to start diet modification (HR = 0.99). Being female (HR = 0.69) and non‐Hispanic whites (HR = 0.60) were associated with a lower likelihood of diabetes incidents. Conclusions: These findings highlight the importance of preparing public health responses for future events that limit access to routine care, particularly for individuals with or at risk of diabetes. Strengthening both in‐person and virtual primary care services is critical to reducing gaps in chronic disease management and to supporting ongoing PCP follow‐up.

  • Open Access

    Feasibility of a Church-Based, CHW-Delivered Diabetes and SDOH Intervention in a Hispanic Community: A Quasi-Experimental Study

    by Elizabeth M. Vaughan, Saad Nadeem, Ashok Balasubramanyam, Craig A. Johnston, Patricia Rodriguez Espinosa, Mukaila Raji, Aanand D. Naik, Gabriela A. Gallegos, Laura R. Porterfield

    Background: Social determinants of health (SDOH) screenings have identified disproportionate inequities in Hispanic populations that increase diabetes risk, yet they rarely lead to interventions. Churches are trusted community hubs with the potential to address health needs; however, partnerships with Hispanic churches remain largely unexplored. Objective: To assess the feasibility of a church-based, community health worker (CHW)–led program to identify and address SDOH inequities in a Hispanic community. Design: Pilot quasi-experimental feasibility study Participants: Forty-seven Hispanic adults, predominantly women (74.5%), with a mean age of 51 years Interventions: Five church congregants obtained CHW state certification (160-h course) and received training in teaching skills, diabetes self-management, and SDOH. With ongoing mentoring, CHWs led a 6-month diabetes prevention and self-management program with monthly in-person education and weekly mHealth coaching focused on addressing SDOH inequities in the healthcare access and quality domain. Main Measures: Feasibility was assessed across eight pre-established variables (integration, expansion, demand, implementation, limited efficacy, acceptability, practicality, and adaptation), including CHWs’ ability to address SDOH inequities such as insurance coverage, established medical home, primary care utilization, eye exams, medication access, and glucose monitoring. Key Results: CHWs completed 97.3% of planned weekly mHealth contacts, identified and addressed 92.8% of participant concerns, and conducted all in-person education sessions per protocol. Healthcare access improved significantly: insurance coverage/clinic eligibility (66.0 to 85.1%; p = 0.025), established medical home (61.7 to 91.5%; p < 0.0001), time since last primary care visit (16.2 to 1.4 months; p = 0.017), and annual eye exams (25.0 to 64.3%; p < 0.0001). On a 5-point Likert scale, participants increased access to medications (Δ = 0.54; p = 0.03), medical care (Δ = 0.67; p = 0.012), and a primary care provider (Δ = 0.79; p = 0.009). Among participants with diabetes, glucose monitoring increased from 0.5 to 1.4 times daily ( p = 0.017). Conclusions: Findings support the feasibility of partnering with Hispanic churches to both identify and address healthcare access SDOH inequities.

  • Open Access

    Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP‑1 receptor agonist use

    by Laura R. Porterfield, Saad Nadeem, Dallin Swanson, Salim S Hayek, Elizabeth M Vaughan

    Purpose of review To evaluate the evidence supporting combined sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes, focusing on cardiometabolic outcomes and practical treatment approaches. Recent findings Cardiovascular outcomes trials and real-world studies indicate that SGLT2is and GLP-1RAs confer complementary, non-redundant cardiovascular, kidney, and metabolic benefits. SGLT2is primarily reduce hospitalization for heart failure and slow kidney disease progression, while GLP-1RAs more effectively reduce atherosclerotic events, particularly stroke; dedicated kidney-outcome and heart-failure trials of GLP-1RAs in chronic kidney disease and obesity-related heart failure with preserved ejection fraction have further broadened their role. Randomized data show that each class retains its benefit irrespective of background use of the other, supporting independent mechanisms; whether this translates into reductions in hard outcomes is being tested prospectively. Emerging evidence supports a phenotype-guided approach that aligns therapy with dominant comorbidities such as atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, and obesity. Summary Despite advances in pharmacotherapy, substantial cardiometabolic risk remains in type 2 diabetes. Combined SGLT2i and GLP-1RA therapy addresses multiple risk domains through complementary mechanisms and may be most effective within a phenotype-guided framework. This framework prioritizes therapy according to predominant comorbidity and reserves combination treatment for individuals with overlapping high-risk phenotypes.


  • Open Access

    Parenthood in US Medical Training Across Specialty Groups: Scoping Review

    by Zuleica M Santiago Delgado, Elizabeth M Vaughan, Mary E Jones, Forrest Jones, Dylan Bridwell, Laura R Porterfield

    Background: Residency and fellowship are demanding phases characterized by intense schedules, limited autonomy, sleep deprivation, and hierarchical environments. Training years often coincide with peak reproductive age, presenting trainees with the dilemma of delaying parenthood or managing training and parenthood concurrently. Objective: This scoping review examines recent literature on factors influencing the experiences of male and female physician trainee parents across various specialties. Methods: Four databases were searched for studies published from January 2014 through January 2025 examining pregnancy, parenthood, or lactation outcomes among physician trainees and distinguishing between specialties. Eligible studies were screened, data extracted using predefined criteria, and findings thematically coded. Chi-square and Fisher exact tests assessed specialty-related differences for each theme. Results: The authors identified 15,861 records, removed 6440 duplicates, and excluded 8989 records. Further, 432 full-text papers were reviewed, with 105 papers included in the final analysis: surgical (n=59), medical subspecialty (n=30), primary care (n=11), and multiple specialties (n=5). Surgical and medical subspecialty studies more often identified interpersonal and policy challenges than primary care. Surgical studies highlighted issues such as pregnancy-related bias, lack of support, rigid schedules, and training-parenthood conflict. Primary care studies more often identified conflicts between parenthood and patient care responsibilities (primary care: 3/11, 27% vs surgical: 3/59, 5% and medical subspecialty studies 0/30, 0%, P =.01). Negative well-being impacts from training and parenthood were reported more often in primary care (3/11, 27%) and surgical studies (13/59, 22%) than in medical subspecialties (1/30, 3%, P =.03). Conclusions: Trainees face physician parenthood challenges across social ecological levels, with surgical and subspecialty trainees experiencing more systemic barriers and primary care trainees more patient care–related concerns.

  • Open Access

    Structured Telehealth Community Health Worker–Clinician Feedback and Diabetes Outcomes

    by Elizabeth M. Vaughan, Xiaoying Yu, Amber B. Amspoker, Aanand D. Naik, Ashok Balasubramanyam, Craig A. Johnston, Christi M. Ballantyne, Salim S. Virani, H. Shelton Brown, Kristina Mena, et al.

    Importance: Community health workers (CHWs) improve chronic disease management in underserved populations, but scalable integration strategies are limited. Objective: To evaluate whether a multidimensional intervention incorporating telementored CHWs and a structured participant-CHW-clinician feedback loop can improve diabetes outcomes. Design, Setting, and Participants: This 12-month randomized clinical trial was conducted at 3 institutionally and geographically diverse community clinics in Texas between September 1, 2023, and April 30, 2025, and included low-income, uninsured White Hispanic adults with type 2 diabetes identified through clinic databases. Data were analyzed between May 1 and July 31, 2025. Intervention: Individuals were randomized 1:1 to the intervention or control. For the intervention, CHWs delivered (1) group diabetes education, (2) individualized telehealth-based coaching, and (3) a novel participant-CHW-clinician feedback loop to facilitate communication, address participant concerns, and improve care coordination. The control was usual care (quarterly clinician visits and access to multidisciplinary and social services). Main Outcomes and Measures: The primary outcome was baseline to 12-month change in hemoglobin A 1c (HbA 1c ) level. Secondary outcomes included changes in cholesterol levels, American Diabetes Association (ADA) guideline adherence, participant recruitment, intervention fidelity, and feedback loop issue resolution. Results: Of 257 participants included in the intention-to-treat analysis (mean [SD] age 54 [11] years; 166 [64.6%] female), 129 were in the intervention group and 128 were in the control group. The intervention reduced HbA 1c (net difference, −1.0 [95% CI, −1.5 to −0.4] percentage points [pp]; P = .001), total cholesterol (net difference, −35.4 mg/dL; 95% CI, −54.6 to −17.2 mg/dL; P = .02), and low-density lipoprotein cholesterol (net difference, −29.7 mg/dL; 95% CI, −44.5 to −14.9 mg/dL; P < .001) levels compared with control. ADA guideline adherence improved for foot examinations (absolute risk [AR], 19.2 [95% CI, 7.4-30.9] pp; relative risk [RR], 1.65 [95% CI, 1.19-2.27]; P = .03) and urine microalbumin screening (AR, 15.8 [95% CI, 5.3-26.3] pp; RR, 1.24 [95% CI, 1.07-1.43]; P = .048). CHWs addressed 490 participant concerns (87.2%) via the feedback loop, including medication refills, glucose management, and access to care. Conclusions and Relevance: In this randomized clinical trial, the CHW intervention significantly improved diabetes outcomes in low-income settings, potentially by reducing fragmentation through structured feedback. Findings also highlight limitations in usual care, underscoring the need for scalable strategies to strengthen chronic disease management in low-income populations. Trial Registration: ClinicalTrials.gov Identifier: NCT04835493

  • Top Cited Papers

    Global Burden of Cardiovascular Disease: What Should Be Expected in the Next 25 Years?

    by Unaiza Naeem, Salil Deo, Amirhossein Sahebkar, Sana Sheikh, Adeel Khoja, Elizabeth M. Vaughan, Ali bin Abdul Jabbar, Dinesh K. Kalra, Leandro Slipczuk, Salim Shahbuddin Virani

    Purpose of Review The aim of this review is to evaluate the evolving burden of cardiovascular disease (CVD) between 2025 and 2050. Recent Findings Between 1990–2023, CVD deaths increased from 13.1 million to 19.2 million, with prevalence rising from 311 to 626 million cases. Most CVD burden is attributable to modifiable risk factors, led by high systolic blood pressure (SBP). Summary By 2050, CVD mortality will reach 35.6 million deaths annually, while prevalence will be at 1.14 billion cases globally. Metabolic, environmental and behavioral determinants will be key drivers, varying across regions according to sociodemographic index. Age-standardized mortality rates will decline, but absolute numbers of people living with CVD will rise due to population growth, aging, and possibly also improved access to care, especially in low-middle income countries. Prevention strategies, early detection and treatment, and better implementation of what is already known are necessary to address this burden.


  • Open Access

    Age-related variations in HbA1c improvements: insights from a telehealth-supported community-based intervention

    by Laura Porterfield, Xiaoying Yu, Amber B Amspoker, Craig A Johnston, Aanand D Naik, Salim S Virani, Christie M Ballantyne, Ashok Balasubramanyam, Elizabeth M Vaughan

    Background and Objectives: We previously demonstrated that a telehealth-supported community health worker (CHW) intervention significantly improved clinical outcomes in diabetes care. However, the extent to which these benefits vary across different age groups remains unclear. This study evaluated the effectiveness of a CHW-led multidimensional diabetes intervention in reducing HbA1c across age groups. Research Design and Methods: We conducted a retrospective analysis of 10 studies (n = 301) that focused on low-income Hispanic adults with or at risk for type 2 diabetes. The intervention included CHW-participant coaching via mobile Health (mHealth), monthly CHW-led group education, and bidirectional mHealth feedback among participants, CHWs, and clinicians. Outcomes included HbA1c changes from baseline to 6 months and an analysis of CHW-participant conversation data. Results: HbA1c levels improved across all age groups from baseline to 6 months, with statistically significant reductions observed in individuals aged 40-66 years (p < .05). As age increased from 40 to 49 years (n = 78), HbA1c reductions ranged from −0.83% to −1.18% (p = .013 to p < .001). By age 50-65 years (n = 182), the trend reversed, with smaller improvements observed as age increased (−1.16% to −0.61%, p < .001 to p = .016). Beyond 65 years (n = 27), HbA1c changes plateaued and were not statistically significant. Medication-related concerns were more prevalent among adults ≥65 years (73.7%) compared to those <65 years (44.1%) (p = .014). Discussion and Implications: HbA1c improved across all ages except in older adults, suggesting that age may play a role in intervention effectiveness. Targeted strategies and further research are needed to understand and address these age-related differences.

  • Open Access

    Clinical course and treatment outcomes in solid-basaloid adenoid cystic carcinoma of the breast: A systematic review and case report

    by Stephanie Kim, Kyle Sheth, Xiaoying Yu, Laura Porterfield, Elizabeth M. Vaughan


  • The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes

    by Kyle Sheth, Stephanie Kim, Laura Porterfield, Salim S. Virani, Shikha Wadhwani, Elizabeth M. Vaughan

    Purpose of Review This review summarizes recent advances in the clinical applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond their established role in glycemic control for type 2 diabetes (T2DM). Recent Findings Originally developed for glycemic control in T2DM, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now being utilized for a range of additional diseases and conditions. Strong evidence supports their efficacy in inducing clinically meaningful weight loss in individuals with overweight or obesity. Further studies have demonstrated cardiovascular benefits, kidney-protective effects, and therapeutic potential in obesity-related conditions such as obstructive sleep apnea and metabolic-associated steatotic liver disease. Emerging data also suggest possible roles in treating substance use disorders, including alcohol and nicotine dependence, though findings remain preliminary and variable. Despite these promising developments, GLP-1RAs are associated with side effects and high costs, contributing to variability in patient access. Summary The therapeutic scope of GLP-1 receptor agonists extends beyond diabetes to multiple other conditions. Broader adoption requires careful evaluation of safety, cost, and evidence for less-established indications.